natgillin/translations-raw huggingface dataset:
(Polyvinylklorid)pose med 200 ml, 400 ml, 600 ml, 800 ml, 1000 ml, 1200 ml, 1400 ml, 1600ml, 1800 ml eller 2400 ml opløsningsmiddel.
(polyvinylchloride) bag of 200ml, 400ml, 600ml, 800ml, 1000ml, 1200ml, 1400ml, 1600ml, 1800ml or 2400ml of diluent
(Postoperativ) hævelse af led
(postoperative) joint swelling
(potent CYP450-induktor;
[potent CYP450 inducer; CYP3A4
(PPP*: N= 251; ITT**: N= 313)
(PPP*: N=251; ITT**: N=313)
(primært endepunkt):
(Primary end-point):
(primært på grund af intestinal BCRP-
(primarily due to intestinal BCRP inhibition
(primært på grund af intestinal BCRP-
(primarily due to intestinal BCRP inhibition)
(Primært) endepunkt 1
(Primary) endpoint 1
(procentpoint)
(percentage point)
(produceret i V. cholerae O1 Inaba, klassisk biotype, stamme 213)
(produced in V. cholerae O1 Inaba, classical biotype strain 213.)
(præ- og postoperativ)
(pre- and
(PT med risiko)
(PT at Risk)
(PVC/alu)
(OPA/Alu/PVC//PET/Alu)
(PVC/alu)
blister (PVC/Alu)
(PVC/alu)
dose)
(PVC/alu)
EU/1/09/551/013
(PVC/PCTFE/Al)
EU/1/15/1010/022
(PVC/PE/PCTFE)
blister (PVC/PE/PCTFE)
(PVC/PVDC/alu)
dose)
(PVC/PVDC/Alu)
EU/1/13/891/004 EU/1/13/891/005
(PVC/PVDC/Alu)
EU/1/13/891/014 EU/1/13/891/015
(PVC/PVDC/Alu)
EU/1/13/891/023 EU/1/13/891/024
(PVC/PVDC/Aluminium)
(PVC/PVDC/alu)
(PVC/PVDC/aluminium)
Administration
(PVC/PVDC/Aluminium)
EU/1/97/046/033
(PVD/PVDC/Alu)
(PVC/PVDC/Alu)
(PVdC/PVC/alu)
blister (PVdC/PVC/alu)
(påvirker 1 til 10 brugere ud af 1.000)
(affects 1 to 10 users in 1,000)
(påvirker 1 til 10 brugere ud af 10.000)
(affects 1 to 10 users in 10,000)
(påvirker 1 til 10 brugere ud af 100)
(affects 1 to 10 users in 100)
(påvirker flere end 1 bruger ud af 10)
(affects more than 1 user in 10)
(påvirker færre end 1 bruger ud af 10.000)
(affects less than 1 user in 10,000)
(raltegravir 400 mg enkeltdosis +
(raltegravir 400 mg single dose +
(raltegravir 400 mg enkeltdosis)
boceprevir (raltegravir 400 mg Single Dose)
(raltegravir 400 mg enkeltdosis)
efavirenz (raltegravir 400 mg Single Dose)
(raltegravir 400 mg hver 12. time +
(raltegravir 400 mg every 12 hours +
(raltegravir 400 mg to gange
(raltegravir 400 mg Twice Daily)
(raltegravir 400 mg to gange dagligt)
(raltegravir 400 mg Twice Daily)
(raltegravir 400 mg to gange dagligt)
calcium carbonate antacid (raltegravir 400 mg Twice Daily)
(raltegravir 400 mg to gange dagligt)
etravirine (raltegravir 400 mg Twice Daily)
(raltegravir 400 mg to gange dagligt)
maraviroc (raltegravir 400 mg Twice Daily)
(raltegravir 400 mg to gange dagligt)
midazolam (raltegravir 400 mg Twice Daily)
(raltegravir 400 mg to gange dagligt)
tenofovir (raltegravir 400 mg Twice Daily)
(registreret som GlaxoWellcome Operations) Harmire Road
(trading as GlaxoWellcome Operations) Harmire Road
(Rifabutin er en induktor af og substrat for CYP3A.) Der er observeret øget systemisk eksponering af darunavir ved samtidig brug af rifabutin (150 mg hver anden dag) og PREZISTA administreret sammen med 100 mg ritonavir.
(Rifabutin is an inducer and substrate of CYP3A.) An increase of systemic exposure to darunavir was observed when PREZISTA co-administered with 100 mg ritonavir was co-administered with rifabutin (150 mg once every other day).
(ritonavir 100 mg dagligt + Victrelis
(ritonavir 100 mg daily + Victrelis
(Ritonavir 200 mg to
(Ritonavir 200 mg
(Ritonavir 200 mg to
(Ritonavir 200 mg twice
(Ritonavir 200 mg to
(Ritonavir 200 mg twice daily)
(Ritonavir 200 mg to gange daglig)
(Ritonavir 200 mg twice
(Ritonavir 600 mg to
(Ritonavir 600 mg twice
(ritonavir 600 mg to
Avanafil (ritonavir 600 mg BID)
(Ritonavir 600 mg to gange daglig)
(Ritonavir 600 mg twice
(Ritonavir, 200 mg to
(Ritonavir, 200 mg
(RRR = 4,0 %, CI: -22,5 til 11,7 [p=0,639]).
(RRR = -4.0%; CI: -22.5 to 11.7 [p=0.639]).
(rødprikket) misfarvning af huden
coldness of the extremities
(S)- methopren (mg)
(S)-methoprene (mg)
(S)-methopren er en insekt vækst regulator (IGR) der tilhører stofgruppen ”juvenile hormon- analoger”, som hæmmer udviklingen af immature insektstadier.
(S)-Methoprene is an insect growth regulator (IGR) of the class of compounds known as juvenile hormone analogues that inhibit the development of immature stages of insects.
(S)-methopren regulerer insekters vækst og blokerer loppers livscyklus ved at dræbe æggene og standse loppernes udvikling i et tidligt stadium, så de dør.
(S)-Methoprene is an insect growth regulator which stops the flea life cycle by killing eggs and blocking the development of juvenile flea stages and causing their death.
(S-warfarin), CYP2C19 (omeprazol) og CYP3A4 (midazolam).
(S-warfarin), CYP 2C19 (omeprazole) and CYP3A4 (midazolam).
(sandsynlig interaktionsmekanisme)
Darunavir/ritonavir
(saquinavir/ritonavir
studied.
(saquinavir/ritonavir)
Clozapine
(saquinavir/ritonavir)
Ethinyl estradiol (saquinavir/ritonavir)
(saquinavir/ritonavir)
Interaction
(saquinavir/ritonavir)
Lovastatin
(saquinavir/ritonavir)
Rapamycin
(saquinavir/ritonavir)
relevant.
(Scoreb) Uge 52
(Scoreb)Week 52
(se også pkt.
adjustments (see also
(se pkt.
(see section
(se pkt.
(see section 4.3).
(se pkt.
(see section 4.4)
(se pkt.
0.82
(se pkt.
1.07
(se pkt.
cases (see section 4.4)
(se pkt.
ection 4.4)
(se pkt.
Narcotic analgesics
(se pkt.
vein thrombosis) (see
(SeeUnited Kingdom)
(See United Kingdom)
(sjælden - kan berøre op til 1 ud af 1.000 patienter)
(rare - may affect up to 1 in 1,000 people)
(sjælden)
Palpitations
(sjælden)
Vasospasm (rare)
(sjælden),
(rare)
(sjælden),
fibrillation (rare),
(sjælden),
fibrillation (rare), QT
(sjælden), Torsades de pointes (sjælden), Bradykardi (sjælden), Karspasme (sjælden)
Ventricular fibrillation (rare), QT prolongation (rare), Torsade de pointes (rare), Bradycardia (rare), Vasospasm (rare)
(solopgang: morgen dosis  (sol: middags dosis) og (måne: aften dosis).
(sunrise; morning dose)  (sun; daytime dose) and (moon; evening dose).
(solvens)
1ml (solvent)
(stabil vedligeholdelse, 35-100 mg én
(stable maintenance, 35-100 mg once
(stabil vedligeholdelse, 35-100 mg én
Methadone/Efavirenz (stable maintenance, 35-100 mg once daily/600 mg once daily)
(standardafvigelse)
(standard deviation)
(statin-intolerant)
(statin intolerant)
(studie DB2113374)
(Study DB2113374)
(studie ZEP117115)
(Study ZEP117115)
(sulfa/trim) / lamivudin (160 mg / 800 mg én gang daglig i 5 dage / 300 mg
Trimethoprim/sulfamethoxazole (Co-trimoxazole)/Lamivudine (160 mg/800 mg once daily for 5 days/300 mg single dose)
(SureClick)
Administration
(Svag hæmning af det intestinale CYP3A4- enzym.)
(mild intestinal CYP3A4 enzyme inhibition)
(symptomer på senebetændelse)
tendon pain (tendinitis like symptoms)
(Særnavn)
(Invented) name
(Særnavn) Navn
(Invented)
(Særnavn) Navn
EU/1/00/133/018
(Særnavn) Navn
EU/1/15/1010/026
(Særnavn) Navn
EU/1/15/991/001
(Særnavn) Navn Bosulif
(Invented) name
(Særnavn) Navn Memantine LEK
(Invented) name Memantine LEK
(Særnavn) Navn Mysimba
(Invented) name
(Særnavn) Navn Optruma
(Invented) name
(søer og gylte)
and gilts)
(t) Estimeret udfra 16,403 melanomer med annoterede BRAF-kodon 600-mutationer i den offentlige COSMIC database,udgivelse 71 (november 2014).
(t) Estimated from 16,403 melanomas with annotated BRAF codon 600 mutations in the public COSMIC database, release 71 (November 2014).
(tabletovertræk) shellac, macrogol, propylenglycol, polysorbat 80, indigotin I (E132), vandfri ethanol, isopropylelkohol, butylalkohol og ammoniakopløsning.
(tablet coating) shellac, macrogol, propylene glycol, polysorbate 80 and indigo carmine colour (E132), ethanol anhydrous, isopropyl alcohol, butyl alcohol, ammonium hydroxide
(tacrolimus 0,5 mg enkeltdosis +
(tacrolimus 0.5 mg single dose +
(taget om aftenen)
in the evening)
(Telzir 1.400 mg 2 gange daglig)
twice daily
(tenofovir 300 mg dagligt + Victrelis
(tenofovir 300 mg daily + Victrelis
(timer)
12.7
(timer)
28.6
(timer)
Mean±SD
(timer) †
0.55
(Tlf.) +31 24 371 7310
6545 CG Nijmegen Netherlands (Tel) +31 24 371 7310
(TPV/r 500/100 mg x 2)
(TPV/r 500/100 mg BID)
(TPV/r 750/200 mg x 2)
(TPV/r 750/200 mg BID)
(trading as Glaxo Wellcome Operations) Priory Street, Ware
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) Priory Street, Ware
(TSH)
stimulating
(tørstof) og
and 1ml of
(uden blisterpakning)
(non-blister)
(uden blisterpakning)
Packaging
(uden blue box-information – kun til pakning sammen med Altera-nebulisatoren)
(No Blue Box - for use only for co-packaging with Altera Nebuliser Handset)
(Udfyldes af lægen)
(To be completed by physician)
(UDP-G-induktion)
concentrations: CYP3A4 induction)
(uge 16)
(Week 16)
(uge 24)
(Week 24)
(uge 54)
(Week 54)
(uge 98)
(Week 98)
(UGT-hæmning)
(UGT inhibition)
(UGT-induktion)
(UGT induction)
(unit dose) 105 tabletter
105 tablets
(vand til injektionsvæsker, benzylalkohol, benzalkoniumklorid)
(water for injections, benzyl alcohol, benzalkonium chloride)
(vCP97): mindst 7,2 log 10
(vCP97): at least 7.2 log 10
(vCP97): mindst 7,2 log 10 CCID50
(vCP97): at least 7.2 log 10
(ved
(when used
(ved 400 mg dosis)
(at dose 400 mg)
(ved 800 mg dosis)
(at dose 800 mg)
(vedhæftet som en sammenfoldet seddel direkte på den indre pakning)
(attached as concertina label directly to the immediate package)
(vedligeholdel se)
(maintenance)
(vedligeholdel se) (N = 195)
(maintenance) (N = 195)
(vedligeholdel se) (N = 221)
(maintenance) (N = 221)
(venøs)b,d
Thrombo- embolism (venous)b,d
(virkning på P-gp-transporten i
(effect on P-gp transport in the
(VTEt)
Haematochezia
(vulpes
achets
(Vulvo) vaginal svampeinfektion
(Vulvo) vaginal fungal infection
(w) Censurerede resultater på overkrydsningstidspunktet
(w) Censored results at time of cross-over
(x) Ikke-stratificeret log-rank test for PFS og Chi-kvadrat-test for samlet responsrate.
(x) Unstratified log-rank test for PFS and Chi-squared test for Overall Response Rate.
(y) Per 30.december 2010 var i alt 549 patienter evaluerbare for PFS, og 439 patienter var evaluerbare for den samlede responsrate.
(y) As of December 30, 2010, a total of 549 patients were evaluable for PFS and 439 patients were evaluable for overall response rate.
(yderligere prøve for
(additional test to
(yderligere reduktion til 15 mg, hvis 30 mg ikke tolereres godt)
(further reduction to 15 mg if 30 mg are not well tolerated)
(Ydre æske med én 28-dages pakning med Cayston og én Altera-nebulisator med blue box- information)
(Outer carton containing one 28-day pack of Cayston and one Altera Nebuliser Handset with a Blue Box)
(z) Per 1. februar 2012 var i alt 675 patienter evaluerbare for opdatering af post hoc-analyse af PFS.
(z) As of February 01, 2012, a total of 675 patients were evaluable for the post-hoc analysis update of PFS.
(~ 8,8 µg/kg)1
(~8.8µg/kg) 1
(µg.t/ml)
(µg.hr/ml)
(Æske med 3 pipetter)
(Box of 3 pipettes)
(Øget) forekomst af blodpropper.
Thromboembolic events, e.g. increase in blood clots.
(μM●t)
AUC0-12hr (μM●hr)
(↑ clarithromycin fra CYP3A-hæmning og
(↑ digoxin from probable inhibition of
(↑ digoxin fra en sandsynlig hæmning af
(↑ digoxin from probable inhibition of
(↓ darunavir fra CYP3A-induktion)
Darunavir: comparison of
(≥ 1/1.000 til < 1/100)
(≥ 1/1000 to < 1/100)
(≥ 1/100 til < 1/10)
(≥ 1/100 to < 1/10)
(≥ 10 IE/ml)
(≥ 10 IU/mL)
(≥1/1.000 til
(≥ 1/1,000 to
(≥1/100 til
(≥ 1/100 to
( 24 dage)
( 24 days)
( 1/100, < 1/10) og ikke almindelig ( 1/1.000, < 1/100)
< 1/10; and uncommon  1/1000, < 1/100.
( 10 mIE/ml)
( 10 mIU/ml)
(1/10.000,
Rare (1/10,000,
(2) a
fractures (2) a
) Navn
(Invented) name
) opløsning til injektion eller 5% w/v glukoseopløsning).
9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution).
); diarré (G3/4: 3,4 %); konstipation (G3/4: 0,5
Diarrhoea (G3/4: 3.4%); Constipation (G3/4: 0.5%)
); febril neutropeni
Thrombocytopenia (G3/4: 4.0%); Febrile neutropenia
); G3/4 Forhøjet ALAT (1,3 %)
G3/4 ALT increased (1.3%)
); G3/4 Forhøjet ASAT (< 3 %); G3/4
increased (<3%); G3/4
); Hudsygdomme (G3/4: 0,6 %);
Skin disorder (G3/4: 0.6%);
); Misfarvning af negle; Onycholysis (G3/4: 1 %)
Nail discolouration; Onycholysis (G3/4: 1%)
); opkastning (G3/4: 0,6 %)
Vomiting (G3/4: 0.6%)
); opkastning (G3/4: 1,2 %)
Stomatitis/Pharyngitis (G3/4: 0.9%); Vomiting (G3/4: 1.2%)
); Opkastning (G3/4: 5 %); Konstipation
Vomiting (G3/4: 5%); Constipation
); Pyreksi (G3/4: 0,6 %);
Pyrexia (G3/4: 0.6%); Fluid retention; Oedema
); somnolens (G3/4: 0 %)
Neurotoxicity (G3/4: 0%); Somnolence (G3/4: 0%)
); trombocytopeni (G3/4: 1,6 %); febril neutropeni (G3/4: NA)
Thrombocytopenia (G3/4: 1.6%); Febrile neutropenia (G3/4: NA)
); trombocytopeni (G3/4: 5,2 %)
Thrombocytopenia (G3/4: 5.2%)
+ + forholdet af CD4 /CD8 i cerebrospinalvæsken præ- og postvedolizumab administration hos raske, frivillige forsøgspersoner.
+ + change in the ratio of CD4 /CD8 in cerebrospinal fluid pre- and post-vedolizumab administration in healthy human volunteers.
+ 1 fyldt injektions- sprøjte (multipakning)
1 pre-filled syringe (multipack)
+ 1 inhalator
1 inhaler
+ 1 kanyle
+ 1 injection needle
+ 1 kanyle
+ 1 needle
+ 1 kanyle
EU/1/02/221/006
+ 1 kanyle
EU/1/02/221/008
+ 1 pakke med
1 cartridge + 1 pack
+ 1 steril hætte med ventil
(Invented) name
+ 1 venepunktursæt
EU/1/15/1076/003
+ 1 venepunktursæt
EU/1/15/1076/005
+ 1 venepunktursæt
EU/1/15/1076/009
+ 10 kanyler
+ 10 needles
+ 10 kanyler
EU/1/06/357/001
+ 10 nål
+ 10 needles
+ 100 kanyler
yringes + 100
+ 12 (2 x 6) kanyler (multipakning)
6) injection needles (multipack)
+ 12 kanyler
+ 12 needles
+ 12 kanyler + 12 etui til pennen
+ 12 needles + 12 pen covers
+ 2 enheder
+ 2 units
+ 2 kanyler
2 needles
+ 2 pakker med
1 cartridge + 2 packs
+ 2 pakker med
Pack size
+ 2 sprøjter +
+ 2 syringes
+ 2,5 mg letrozol/dag
+ Letrozole 2.5 mg /day
+ 20 kanyler
+ 20 needles
+ 20 kanyler
EU/1/06/357/005
+ 20 kanyler
EU/1/06/357/020
+ 20 nål
+ 20 needles
+ 20 nåle
injection
+ 3 kanyler
+ 3 needles
+ 3 kanyler (25, 38 og 50 mm)
needles (25, 38 and 50 mm)
+ 3 kanyler (25, 38 og 50 mm)] (flerpakning)
needles (25, 38 and 50 mm)] (multipack)
+ 3 pakker med
1 cartridge + 3 packs
+ 351 219 245 020
Tel: + 357 24813333
+ 3TC
ZDV + 3TC
+ 4 enheder
+ 4 units
+ 4 kanyler
+ 4 injection needles
+ 4 kanyler
+ 4 needles
+ 4 kanyler
syringes + 4 injection needles
+ 4 kanyler + 4 etui til pennen
+ 4 needles + 4 pen covers
+ 40 kanyler
yringes + 40
+ 50 mg/ml (5 %) glucoseinjektionsvæske
+ dextrose 50 mg/ml (5%) solution for injection
+ 50 mg/ml (5 %) glucoseinjektionsvæske
+dextrose 50 mg/ml (5%) solution for injection
+ 50 mg/ml (5 %) glucoseinjektionsvæske bør ikke bruges til infusioner af varighed på mere end 1 time.
+ Dextrose 50 mg/ml (5%) solution for injection should not be used for infusion durations greater than 1 hour.
+ 6 enheder
+ 6 units
+ 7 x 15 mg + 7 x 20 mg tabletter
+ 7 x 15 mg + 7 x 20 mg tablets
+ 7 x 15 mg + 7 x 20 mg)
+ 7 x 20 mg)
+ 8 enheder
+ 8 units
+ Arter med > 50 % erhvervet resistens i én eller flere medlemsstater
+ species with > 50% acquired resistance in one or more Member State
+ Avastin 7,5 mg/kg
+ Avastin
+ baggrunds- regime n = 351
+ background regimen n = 351
+ Baseret på LOCF med 'last on-drug observation carried forward'.
+ Based on LOCF with the last on-drug observation carried forward.
+ carboplatin (N = 521)
+ carboplatin (N=521)
+ carboplatin (N = 531)
+ carboplatin (N=531)
+ docetaxel N=107
+Docetaxel N=107
+ docetaxel)
[5.9; 18.8]
+ frekvens for erhvervet resistens >50% i nogle medlemslande
+ frequency of acquired resistance > 50 % in some Member States
+ GP
Bival + GP
+ Hændelsesrater baseret på Kaplan-Meier-estimater efter 3 år.
+ Event rates based on Kaplan-Meier estimates at 3 years.
+ infektion, oral herpes
Back pain,
+ interferon alfa-2b 3 MIE/m2 3 gange om ugen
+ interferon alfa-2b 3 MIU/m2 3 times a week
+ Med 'baseline observation carried forward' (BOCF)
+ With baseline observation carried forward (BOCF)
+ met 1.000 mgc
+ Met 1000 mgc
+ OB
+ OBT
+ OB N=426
+ OBT N=426
+ OBR N=294
N=294
+ OBR N=296
N=296
+ Odds ratio og p-værdi stammer fra en logistisk regressionsmodel korrigeret for ECOG-funktionsstatus ved baseline (0 versus 1).
+ Odds ratio and p-value were obtained from a logistic regression model adjusted for baseline ECOG Performance Score (0 versus 1).
+ og CD8
+ and CD8
+ proteasehæmmere, se nedenfor.
etravirine + PI, see below.
+ ribavirin
+ ribavirin (800
+ ribavirin 15 mg/kg/dag
+ ribavirin 15 mg/kg/day
+ ribavirin* N = 2.044
+ ribavirin* N = 2,044
+ ritonavir + emtricitabin og tenofovirdisoproxilfumarat i fastdosis-kombination.
+ emtricitabine and tenofovir disoproxil fumarate fixed-dose combination.
+ solvens:
+ Solvent:
+ solvens: 2 ml
+ Solvent: 2 ml
+ Supplerende dosis er en enkelt tillægsdosis.
+ Supplementary dose is a single additional dose
+ Supplerende dosis er en enkelt tillægsdosis.
+ Supplementary dose is a single additional dose.
+ tællinger (aktivitet) i øverste halvdel
Counts (activity) in bottom half Counts(activity) in bottom half + Counts(activity) in top half
+ Varicella forårsaget af vaccinestamme er set ved brug af levende varicellavaccine (Oka/Merck) efter markedsføring.
+ Varicella caused by vaccine strain was observed in post-marketing use with Varicella Vaccine live (Oka/Merck).
+ Victrelis 800 mg tre gange dagligt)
Victrelis 800 mg three times daily)
+**Telithromycin er ikke aktivt mod organismer, der grundlæggende udtrykker MLSB- resistensdeterminanten (cMLSB).
+ Telithromycin is not active against organisms that constitutively express the MLSB resistance determinant (cMLSB).
+/- DMARDs
+/- DMARDs N=162
+/- DMARDs
+/- DMARDs N=496
+/- DMARDs
+/- DMARDs N=497
+/- strålebehandling] (%) (95% CI)
+/- radiotherapy] (%) (95% CI)
+1,0 mg (alle andre patienter)
+1.0 mg (all other patients)
+1,5 mg (kvinde i behandling med oralt østrogen)
+1.5 mg (female on oral oestrogen)
+15,6 bogstaver ved måned 24.I CRYSTAL havde patienter med (N = 53) eller uden (N = 300) iskæmi, som blev behandlet med ranibizumab monoterapi, en gennemsnitlig ændring fra baseline på henholdsvis +15,0 og +11,5 bogstaver.
In CRYSTAL, patients with ischaemia present (N=53) or absent (N=300) and treated with ranibizumab monotherapy had a mean change from baseline of +15.0 and +11.5 letters, respectively.
+1Hvæsende vejrtrækning
+1Wheezing
+1Hypotension
+1 Hypotension
+356 –(0)21-465797 info@agrimedltd.com
Tel.: +356 –(0)21-465797 info@agrimedltd.com
+36 1 288 64 00
Tel.: +36 1 288 64 00
+3TC 1 x dgl. (n=88)
+3TC QD (n=88)
+44 (0)191 -511 -8500 info@shieldtx.com
+44-(0)191-511-8500 info@shieldtx.com
+49 (0) 89 4561 2612 e-mail@msd.de
Tel: 0800 673 673 673 (+49 (0) 89 4561 2612) e-mail@msd.de
+alopeci
+alopecia
+Anafylatisk shock
+Anaphylactic shock
+Andre typer af pegIFN/RBV svigt inklusive mindre vel-dokumenteret non-respons, recidiv/virologisk gennembrud eller anden pegIFN svigt.
+Other types of pegIFN/RBV failure include less well documented non-response, relapse/breakthrough or other pegIFN failure.
+Anæmi,
+Anaemia,
+anæmi, +neutropenisk feber, trombocytopeni
+Neutropenic fever, Thrombocytopenia
+bronkitis
+bronchitis
+Embolisme og tromboser
+Embolism and thrombosis
+embolisme og tromboser
Flushing,
+febril
+febrile
+febril infektion,
+febrile infection,
+Febril neutropeni
+Febrile Neutropenia
+granulocytop
+granulocytopeni
+hjertesygdom
disease, chest
+kulderystelser,
+shivering,
+Letargi,
+Lethargy,
+letargi, temperaturintolerance
+Lethargy, Temperature intolerance
+letargi, temperaturintolerance
Sore throat, Dysaesthesia pharynx
+Leukopeni,
+Leucopenia,
+leukopeni, +anæmi,
weakness
+multiorgan-
+multi-organ
+myokardie-
+myocardial
+myokardie-
Bronchospasm4,
+myokardie- infarkt4 og 6,
orthostatic
+Neutropeni,
+Neutropenia,
+Neutropenisk feber, Trombocytopeni
+Neutropenic fever, Thrombocytopen ia
+Neutropenisk feber, Trombocytopeni
+Neutropenic fever, Thrombocytopenia
+neutropenisk feber, trombocytopeni
Renal and urinary
+optimeret baggrunds (OB)- behandlinga
+Optimised backgrounda
+pancytopeni,
+pancytopenia,
+pneumoni,
+pneumonia,
+RBV 12 uger (n = 217)
12 weeks (n = 217)
+sinusitis,
+sinusitis, hepatitis B1
+supra-
+supraventricu
+supra-
hypotension
+trombo-
openia
+træthed,
+fatigue,
+venstre
hypotension,
+ventrikulær
+cardiac disorder
, 174 med gynækologiske, 300 med gastrointetinale og 487 med andre typer tumorer) og 802 med hæmatologiske maligniteter.
1 895 with solid tumours (683 breast, 260 lung, 174 gynaecological, 300 gastrointestinal, and 478 other tumour types) and 802 with haematological malignancies.
, CI: -5,7 til 18,7 [p=0,258]).
18.7 [p=0.258]).
, gastritis, abdominalsmerter, mundtørhed, abdominalgener, oppustethed, gingivitis, melæna, tandpine
Constipation, dyspepsia, gastritis, abdominal pain, dry mouth, abdominal discomfort, abdominal distension, gingivitis , melaena, toothache
, Hæmaturi, Nokturi, Forøget blodkreatinin
Pruritus, Skin
, som lægemidl et er beregnet til:
Route of administration
, supraventrikul ær takykardie
fibrillatione, supraventricular tachycardiae
, udslæt, hudallergi, urticaria
Photosensitivity, rash, cutaneous allergy, urticaria
,Abstinens- syndromc, indurationc
temperature decreasedc, drug withdrawal syndromec, indurationc
,Lokaliseret ødemA
Localised oedemaA
. Du bør normalt anvende Humalog Mix50 KwikPen indenfor 15 minutter før eller efter et måltid.
You should normally use Humalog Mix50 within 15 minutes of a meal.
. I laboratorieundersøgelser blev der detekteret fald i serumalbumin, globulin, total protein, kalcium og alkalisk fosfatase og stigning i ALT og AST efter administration af produktet ved den anbefalede behandlingsdosis.
In laboratory studies, decreases in serum albumin, globulin, total protein, calcium and alkaline phosphatase and increases in ALT and AST were detected following administration of the product at the recommended treatment dose.
. Levertransplantation
Liver transplant
. Mantener fuera de la vista y del alcance de los niños.
Keep out of the sight and reach of children.
. Opbevares utilgængeligt for børn
Keep out of the sight and reach of children.
. stofsbehandling (ViraferonPeg med ribavirin og boceprevir): Kan anvendes til voksne patienter med genotype 1-CHC.
Tritherapy (ViraferonPeg with ribavirin and boceprevir): applies to adult patients with genotype 1 CHC.
..................................................................................................................................15 mikrogram HA**
................................................................................................................................15 micrograms HA
.BAT
30
.c., i.v.
SC, IV use
.Kapselskallen til 60 mg kapsler indeholder gelatine, titandioxid (E171) og jernoxid, gul (E172)
The capsule shell for the 60 mg capsule contains gelatin, titanium dioxide (E171) and yellow iron oxide (E172).
.Knoglefraktur rapporteredes hos henholdsvis 0,7 % og 0,6 % for canagliflozin 100 mg og 300 mg sammenlignet med 0,3 % for placebo.
Bone fracture was reported in 0.7% and 0.6% for canagliflozin 100 mg and 300 mg, respectively, compared to 0.3% for placebo.
.RUX
.BAT
.Ældre
Elderly
. Betingelser eller begrænsninger med hensyn til sikker og effektiv anvendelse af lægemidlet
Conditions or Restrictions with Regard to the Safe and Effective Use of the Medicinal Product
/ 22 mikrogram
/ 22 micrograms
/ 3 µg r-hLH
Content
/ 3 µg r-hLH
hFSH / 3 µg
/ Antibiotika
Anti- infectious agents
/12,5 mg var 100%, når blodtrykket blev monitoreret ambulant.
CoAprovel 150 mg/12.5 mg were 100%.
/12,5 mg var 100%, når blodtrykket blev monitoreret ambulant.
Karvezide 150 mg/12.5 mg were 100%.
/400 mg én gang dagligt
(200 mg q12h/600 mg once daily)
/5 µg/0,5 ml
5 µg/0.5 ml
/Adipøs (n=2)
Adipose (n=2)
/Adipøs (n=2)
IVR (%/IU/kg)
/blandet)
/mixed)
/CYP3A-hæmning)
(CYP3A inhibition)
/dag (eller derefter om nødvendigt ned til 1,0 mg/m2 /dag).
1.25 mg/m2/day (or subsequently down to 1.0 mg/m2/day if necessary).
/dag)
/day)
/dag). (eller derefter om nødvendigt ned til 1,0 mg/m2 /dag).
1.25 mg/m2/day (or subsequently down to 1.0 mg/m2/day if necessary).
/epiduralanæstesi
or spinal
/epiduralanæstesi
pinal/epidur
/infusionsvæske, opløsning
Solution for injection/infusion
/lamivudin
/lamivudine
/magnesiumhydroxidantacida
hydroxide antacids nor famotidine
/magnesiumhydroxidantacida eller
atovaquone/proguanil with
/magnesiumhydroxidantacida eller
hydroxide antacids nor famotidine
/ml
Units/ml
/monocytkulturer.
Resistance
/mortalitets- hændelse a
Morbidity- mortality event a
/naloxon
/ naloxone
/paritaprev
r/paritapre
/Patienter evalueret (%) (17 %)
response/Patients evaluated (17%)